Sustained Or Differential Release Type Patents (Class 514/964)
-
Patent number: 7001617Abstract: The invention relates to a method to induce apoptosis and to inhibit matrix metalloproteinases in a disease condition in a human or animal by contacting hyperplastic tissue, tumor tissue, or a cancerous lesion with one or more antimicrobial metals, preferably formed with atomic disorder, and preferably in a nanocrystalline form. In another aspect of the invention, there is provided a method of preventing excessive release of matrix metalloproteinases from an inflammatory cell in a disease condition in a human or an animal by contacting the cell with a therapeutically effective amount of a noble metal in a crystalline form characterized by atomic disorder, or with a solution derived therefrom to provide a modulatory effect on one or more matrix metalloproteinases, wherein the one or more noble metals is formed with atomic disorder, and preferably in a nanocrystalline form.Type: GrantFiled: May 30, 2002Date of Patent: February 21, 2006Assignee: Nueryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, John Barrymore Wright, Kan Lam
-
Patent number: 6994873Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.Type: GrantFiled: February 4, 2002Date of Patent: February 7, 2006Assignee: Valpharma S.A.Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
-
Patent number: 6989159Abstract: Once daily pharmaceutical compositions containing lithium carbonate in the form of coated granules.Type: GrantFiled: August 6, 2001Date of Patent: January 24, 2006Assignee: JDS Pharmaceuticals, LLCInventor: Giulio Tarro
-
Patent number: 6989156Abstract: Therapeutic treatments using the direct application of selected structures of antimicrobial metals in free-standing powder form, solution form and/or suspension form in therapeutically effective amounts. The selected structures of antimicrobial metals serve as an antimicrobial agent, an anti-inflammatory agent, an immuno modulator agent, an enzyme modulator agent, and/or an anti-tumor agent, for human and/or animal use.Type: GrantFiled: April 23, 2002Date of Patent: January 24, 2006Assignee: Nucryst Pharmaceuticals Corp.Inventor: Scott H. Gillis
-
Patent number: 6979674Abstract: The present invention relates to the preparation of polyol/thickened oil suspensions containing a biologically active agent, for the sustained delivery of the biologically active agent. The described protein/glycerol/oil suspensions show sustained release of protein, e.g., G-CSF, of up to at least one week.Type: GrantFiled: November 28, 2000Date of Patent: December 27, 2005Assignee: Amgen Inc.Inventors: Merrill Goldenberg, Daxian Shan, Alice Beekman, Tiansheng Li
-
Patent number: 6979468Abstract: A method and composition for the treatment of acne vulgaris, acne rosacea, and other inflammatory skin conditions comprises the oral administration of a composition comprising a dose of nicotinamide delivered at levels substantially in excess of normal dietary levels, the nicotinamide being delivered in combination with zinc. The composition may also include quantities of copper and folic acid. In a most preferred embodiment, the nicotinamide and copper each are present in immediate release formats, while the zinc is present in a sustained release format.Type: GrantFiled: December 6, 2002Date of Patent: December 27, 2005Assignee: Sirius LaboratoriesInventor: Frank Pollard
-
Patent number: 6939568Abstract: The invention relates to the use of one or more antimicrobial metals, most preferably silver, preferably formed with atomic disorder, and preferably in a nanocrystalline form, for the treatment of inflammatory skin conditions. The nanocrystalline antimicrobial metal of choice may be used in the form of a nanocrystalline coating of one or more antimicrobial metals, a nanocrystalline powder of one or more antimicrobial metals, or a solution containing dissolved species from a nanocrystalline powder or coating of one or more antimicrobial metals.Type: GrantFiled: April 23, 2002Date of Patent: September 6, 2005Assignee: Nucryst Pharmaceuticals Corp.Inventors: Robert Edward Burrell, Hua Qing Yin
-
Patent number: 6936187Abstract: Functionalized cubic gel precursors, functionalized cubic liquid crystalline gels, dispersions of functionalized cubic gel particles and functionalized cubic gel particles are disclosed. Methods for preparing and using the precursors, gels, dispersions, and particles are also disclosed. The precursors, gels, dispersions, and particles are used to deliver active ingredients to substrates.Type: GrantFiled: February 14, 2002Date of Patent: August 30, 2005Inventors: Matthew Lawrence Lynch, Patrick Thomas Spicer
-
Patent number: 6936275Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.Type: GrantFiled: February 11, 2003Date of Patent: August 30, 2005Assignee: Scolr, Inc.Inventors: A. Reza Fassihi, Thomas Dürig
-
Patent number: 6929804Abstract: An anti-fungal product for delivering at least two different anti-fungals that is comprised of three dosage forms with different release profiles with each anti-fungal being present in at least one of the dosage forms.Type: GrantFiled: December 16, 2002Date of Patent: August 16, 2005Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6911216Abstract: Delivery of bioactive molecules such as nucleic acid molecules encoding a protein can be significantly enhanced by immobilization of the bioactive molecule in a polymeric material adjacent to the cells where delivery is desired, where the bioactive molecule is encapsulated in a vehicle such as liposomes which facilitates transfer of the bioactive molecules into the targeted tissue. Targeting of the bioactive molecules can also be achieved by selection of an encapsulating medium of an appropriate size whereby the medium serves to deliver the molecules to a particular target. For example, encapsulation of nucleic acid molecules or biologically active proteins within biodegradable, biocompatible polymeric microparticles which are appropriate sized to infiltrate, but remain trapped within, the capillary beds and alveoli of the lungs can be used for targeted delivery to these regions of the body following administration to a patient by infusion or injection.Type: GrantFiled: November 18, 1998Date of Patent: June 28, 2005Assignee: Genzyme CorporationInventors: Laurence A. Roth, Stephen Jack Herman
-
Patent number: 6890888Abstract: A controlled release agricultural absorbent based product including particles of an absorbent material containing capillaries/voids between 10-200 microns in cross-sectional diameter which is impregnated in an amount of 40-95% of the capillaries/voids volume with an agriculturally beneficial material selected from the group consisting of fertilizers, insecticides, herbicides and fungicides, being produced by a process including steps of 1) introducing water to particles of absorbent material to result in absorption of water within the absorbent material, 2) heating the absorbent particles and water to transform the water within the absorbent particles to steam, 3) introducing the heated absorbent particles to an agriculturally beneficial material in aqueous solution to essentially saturate the absorbent particles with the agriculturally beneficial material, 4) granulating the combination of agriculturally beneficial material and saturated absorbent particles to solidify and harden the mixture, resulting in thType: GrantFiled: July 2, 2001Date of Patent: May 10, 2005Assignee: NFT Industries, LLCInventors: Taylor Pursell, Arthur R. Shirley, Jr., Keith D. Cochran, Timothy G. Holt, Gregory S. Pedeen
-
Patent number: 6884885Abstract: The process entails increasing the concentration of cyclodextrin to 15% (w/w) and above to form complexes through a precipitation process in order to increase the yield of complexes, increase the amount of guest complexed, and decrease the particle size of the complex.Type: GrantFiled: December 17, 2001Date of Patent: April 26, 2005Assignee: Cerestar Holding B.V.Inventor: Helena Qi
-
Patent number: 6867229Abstract: Composition which is useful in particular for the treatment and protection of domestic animals which are infested with parasites or are likely to be infested with them, these compositions comprising, in the form of a ready-to-use solution: a) an insecticidal active substance of formula (I), b) a crystallization inhibitor, c) an organic solvent having a dielectric constant of between 10 and 35, preferably of between 20 and 30, d) an organic co-solvent having a boiling point below 100° C., preferably below 80° C., and a dielectric constant of between 10 and 40, preferably of between 20 and 30.Type: GrantFiled: April 8, 2002Date of Patent: March 15, 2005Assignee: MerialInventor: Jean Pierre Etchegaray
-
Patent number: 6846837Abstract: Methods and topical pharmaceutical formulations are provided for the treatment of nail fungus (onychomycosis). The invention involves a pharmacologically active antifungal agent, plus a pharmaceutically acceptable base in a formulation having a pH of 7.5 to about 13.0, preferably about 8.0 to 11.5, and most preferably about 8.5 to 10.5. These basic formulations permeate the nail and are effective in treating fungal infections of the nail and surrounding tissues.Type: GrantFiled: June 21, 2002Date of Patent: January 25, 2005Inventors: Howard I. Maibach, Eric C. Luo, Tsung-Min Hsu
-
Patent number: 6843985Abstract: The present invention is directed to methods and compositions for use to control parasitic mites of honey bees, particularly Varroa mites. In one aspect, the invention is directed to control of parasitic mites of honey bees wherein the active ingredient is a miticidally effective amount of a selected ketone or 1-heptanol, ethyl butyrate, benzaldehyde, heptaldehyde, or d-limonene. In a second aspect, the invention is directed to control of parasitic mites of honey bees wherein the active ingredient is an effective attractant amount of 2-heptanone. The attracted mites are then trapped or otherwise removed from the locus of the bees. The present invention is also directed to methods and compositions which include 2-heptanone to control hive invading pests of honey bees.Type: GrantFiled: February 27, 2002Date of Patent: January 18, 2005Assignees: The United States of America as represented by the Secretary of Agriculture, Cerexagri, Inc.Inventors: Eric H. Erickson, Jr., Gloria DeGrandi-Hoffman, Christian G. Becker, Roy S. Whitson, Thomas A. Deeby
-
Patent number: 6841515Abstract: This invention relates to the production and use of encapsulated and/or concentrically-constructed fertilizer or bioremediation granules such as, for example, granules of 0.5 mm to 10 mm in diameter constructed so that there are at least two components to the granule including a core with a surrounding capsule or a core with one or more concentric layers that are distinguishable from the core with respect to nutrient content, density, hardness, solubility, composition, microbial content and permeability, as in permeability to odors or the permeability of nutrients that might volatize to the atmosphere or leach into the soil. The basic idea was to create a method for manufacturing and using fertilizer granules, which incorporate multiple concentric layers or a core plus an encapsulating outer layer.Type: GrantFiled: January 22, 2002Date of Patent: January 11, 2005Assignee: Unified Enviromental Services Group, L.L.C.Inventor: Jeffrey C. Burnham
-
Patent number: 6838093Abstract: An osmotic system for delivering a pharmaceutically active agent which comprises a core portion, a layer portion enclosing the core portion, and a semipermeable wall portion enclosing the core portion and the layer portion. The core portion includes the pharmaceutically active agent at a first concentration. The pharmaceutically active agent is present in the layer portion at a second concentration. The second concentration is greater than the first concentration. Such a system provides for the osmotic release of the pharmaceutically active agent in release profile other than a zero order release profile, and wherein the release profile is similar to or approaches or reaches a first order release profile.Type: GrantFiled: June 1, 2001Date of Patent: January 4, 2005Assignee: Shire Laboratories, Inc.Inventors: Henry H. Flanner, Lisa C. McKnight, Beth A. Burnside
-
Patent number: 6835398Abstract: A method of treating patients, particularly for pain and/or symptoms of erythromelalgia, and other neurovascular or neuropathic disorders, etc. involves administering high doses of magnesium. The magnesium is introduced through several daily administrations, totaling approximately 2-12 times the RDA for magnesium. These higher levels are achieved through increasing daily dosage amounts gradually in response to patient tolerance and until beneficial results are seen. Total magnesium intake is divided over several doses per day and taken with copious amounts of water.Type: GrantFiled: November 12, 2002Date of Patent: December 28, 2004Inventor: Jay S. Cohen
-
Patent number: 6827930Abstract: A sport fishing system having: a rod and reel, including fishing line; at least one fishing lure or natural bait; and a controlled released fish attractant for applying to the fishing lure or natural bait. The system may further include an applicator for applying the controlled released fish attractant to the fishing lure or natural bait. In the preferred embodiment, the controlled release fish attractant includes: an attractant and a substantially hydrophobic, film forming release agent.Type: GrantFiled: September 6, 2002Date of Patent: December 7, 2004Assignee: Carolina Lunker Sauce, L.L.C.Inventors: Stephen Russell Cobb, Michael D. Jacobson, Joseph A. Lupia
-
Patent number: 6821532Abstract: This invention relates to a composition for use in treating benign prostatic hyperplasia including a saw palmetto extract provided in an oral controlled release formulation which allows release of active ingredients in the intestinal tract and which allows the maintenance of therapeutic levels of active agents in the bloodstream for prolonged periods of time. This invention also relates to a composition for improving the efficacy of a saw palmetto extract, a method of treating benign prostatic hypertrophy, and a method of improving the efficacy of a saw palmetto extract treatment.Type: GrantFiled: November 16, 2001Date of Patent: November 23, 2004Assignee: Unitel Technologies, Inc.Inventors: Sikander Randhava, Surjit Randhava, Sarabjit Randhava
-
Patent number: 6821928Abstract: A method for reducing the rate of diffusion of a slow-release material through a host polymer material to increase the useful life of a slow-release product. An inert fine particulate inorganic material such as an intercalation material having a layered structure is incorporated into a mixture of the slow-release material and the host polymer. The intercalation material has its layers intercalated with molecules of the slow-release material which are accommodated within spaces between the layers of the intercalation material. The particulate material slows the diffusion rate of the slow-release material through the host polymer when compared with the diffusion rate of the same slow-release material through the same host polymer not containing the particulate material. In one embodiment, the intercalation material comprises a nano-clay, the host polymer is a polyolefin, and the slow-release material is a bioactive material such as dinitroanaline.Type: GrantFiled: October 31, 2002Date of Patent: November 23, 2004Inventor: Rodney Ruskin
-
Patent number: 6773627Abstract: Cubic liquid crystalline gel precursors, bulk cubic liquid crystalline gels, and dispersions of cubic liquid crystalline gel particles, and methods for their preparation, are disclosed. The precursors, gels, and dispersions can be used as skin penetration enhancers. The precursors, gels, and dispersions are prepared by methods employing hydrotropes that do not detrimentally affect the cubic liquid crystalline structure of the gels and particles.Type: GrantFiled: December 4, 2003Date of Patent: August 10, 2004Assignee: Children's Hospital Research FoundationInventors: Matthew Lawrence Lynch, Patrick Thomas Spicer
-
Patent number: 6749869Abstract: The mastitis control teat dip composition of the invention provides rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The compositions of the invention are made by combining an aqueous thickened liquid composition containing the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite. The materials can be combined, blended into a smooth viscous material and can be immediately contacted with the target animals. The compositions of the invention provide rapid initial kill, consistent long term kill and chemical and rheological stability.Type: GrantFiled: September 26, 1997Date of Patent: June 15, 2004Assignee: EcolabInventors: Francis L. Richter, Cathy M. Paquette, Richard K. Staub
-
Patent number: 6743445Abstract: A method of coating an active material is provided. The method comprises contacting an active material with a film-forming composition comprising an aqueous dispersion of an amylose-alcohol complex, an insoluble film-forming polymer and a plasticiser at a temperature of less than 60° C. The method finds particular application in the preparation of dosage forms comprising active materials that are unstable at temperatures in excess of 60° C. The compositions prepared in accordance with the method can be used to deliver an active material to the colon.Type: GrantFiled: May 3, 2002Date of Patent: June 1, 2004Assignee: BTG International LimitedInventors: John Michael Newton, Chuei Wuei Leong
-
Patent number: 6733796Abstract: This invention relates to a composition for use in treating benign prostatic hyperplasia including a saw palmetto extract provided in an oral controlled release formulation which allows release of active ingredients in the intestinal tract and which allows the maintenance of therapeutic levels of active agents in the bloodstream for prolonged periods of time. This invention also relates to a composition for improving the efficacy of a saw palmetto extract, a method of treating benign prostatic hypertrophy, and a method of improving the efficacy of a saw palmetto extract treatment.Type: GrantFiled: October 23, 2002Date of Patent: May 11, 2004Assignee: Unitel Technologies, Inc.Inventors: Sikander Randhava, Surjit Randhava, Sarabjit Randhava
-
Patent number: 6730320Abstract: An antibiotic product, in particular a tetracycline, such as doxycycline, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: December 20, 2001Date of Patent: May 4, 2004Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6723347Abstract: A process for conveniently producing a stable protein powder retaining the higher-order structure at a high level which comprises freezing a protein-containing solution at a cooling rate of about −300 to −10° C./min. and then drying.Type: GrantFiled: March 15, 2002Date of Patent: April 20, 2004Assignee: Takeda Chemical Industries, Ltd.Inventors: Yutaka Yamagata, Takayuki Doen, Naoki Asakawa, Shigeyuki Takada
-
Patent number: 6703043Abstract: The invention relates to a device for releasing active agents, characterized in that at a frequency of 0.1 rad/s, it has a glass transition temperature of less than 15° C., contains at least 3% by weight of an SEPS block copolymer and contains at least one substance with a local or systematic effect which does not cause hyperaemia. The device is not foamed.Type: GrantFiled: August 4, 2000Date of Patent: March 9, 2004Assignee: Beiersdorf AGInventors: Peter Himmelsbach, Detlev Radloff
-
Patent number: 6699510Abstract: The mastitis control teat dip composition having a visible indicator aspect of the invention provides a softening, soothing, smoothing, relaxing property, a rapid initial kill, a useful highly pseudoplastic rheology, a barrier/film-forming capacity, a unique antimicrobial composition that is stable over an extended period of time, and unexpected long term microbial control when compared to the prior art materials disclosed in patents and used in the marketplace. The indicator aspect provides ease of visually detecting the material on the animal skin and can indicate efficacy of the material. The compositions of the invention are made by combining an aqueous liquid composition containing the visual indicator combined with the organic components which can be combined with a simple aqueous solution of a salt of chlorous acid, preferably an alkali metal chlorite.Type: GrantFiled: August 19, 2002Date of Patent: March 2, 2004Assignee: Ecolab Inc.Inventors: David D. McSherry, Francis L. Richter
-
Patent number: 6699492Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.Type: GrantFiled: April 22, 2002Date of Patent: March 2, 2004Assignees: InSite Vision Incorporated, SSP Co., Ltd.Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
-
Patent number: 6692775Abstract: A gel formulation is combined with a bactericidal concentrate which is a liquid mixture of about 1000 parts by volume of ultra pure water having an electrical resistance of 16-26 megohms, total dissolved solids of less than 0.04 parts per million and a specific conductance of less than 0.10 mho with about 1.2 to 3 parts by volume of Willard Water as prepared in accordance with U.S. Pat. No. 3,893,943. The bactericidal liquid concentrate in the amount of 3.5 to 12 ml in one liter of gel formulation is applied directly to a skin surface area having a burn or other dermal lesion to protect the area from bacterial contamination.Type: GrantFiled: June 24, 2002Date of Patent: February 17, 2004Assignee: Aqua Med, Inc.Inventor: John D. Young
-
Patent number: 6685958Abstract: The present invention relates to the use of quinolone carboxylic acid formulations in the treatment of ocular and periocular infections. The present invention also relates to sustained release compositions comprising specific quinolone carboxylic acid compounds. The invention also relates to quinolone carboxylic acid compositions and methods of preparing the same.Type: GrantFiled: April 25, 2001Date of Patent: February 3, 2004Assignees: InSite Vision Incorporated, SSP Co., Ltd.Inventors: Samir Roy, Santosh Kumar Chandrasekaran, Katsumi Imamori, Takemitsu Asaoka, Akihiro Shibata, Masami Takahashi, Lyle M. Bowman
-
Patent number: 6673835Abstract: A viscous gel for delivering minor effective amounts of active substances through the nasal membrane into the body.Type: GrantFiled: September 1, 1999Date of Patent: January 6, 2004Assignee: Zicam LLCInventors: Charles Hensley, Robert Steven Davidson
-
Patent number: 6667057Abstract: An antibiotic product, in particular levofloxacin, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: December 20, 2001Date of Patent: December 23, 2003Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6663890Abstract: An antibiotic product, in particular metronidazole, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: December 20, 2001Date of Patent: December 16, 2003Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6663891Abstract: An antibiotic product, in particular an erythromyacin, is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antibiotic product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosage form, as well as two or more delayed release dosage forms, with each of the dosage forms having a different release profile, wherein each reaches a Cmax at different times.Type: GrantFiled: December 20, 2001Date of Patent: December 16, 2003Assignee: Advancis Pharmaceutical Corp.Inventors: Edward M. Rudnic, James D. Isbister, Donald J. Treacy, Jr., Sandra E. Wassink
-
Patent number: 6652890Abstract: The invention described herein encompasses a methods and compositions of treating cancer or solid tumors comprising the administration of a therapeutically effective amount of catechins, a group of polyphenols found in green tea, to a mammal in need of such therapy. Compositions of catechins include but not limited to, epigallocatechin gallate (EGCg), epicatechin (EC), epicatechin gallate (ECG), epigallocatechin (EGC). The unique compositions of the invention contain various combinations of the catechins, alone or in combination with each other or other therapeutic agents and are used to treat primary and metastatic cancers in humans. The invention also encompasses the varying modes of administration of the therapeutic compounds.Type: GrantFiled: March 19, 2002Date of Patent: November 25, 2003Assignee: Purdue Research FoundationInventors: Dorothy M. Morré, D. James Morré
-
Patent number: 6646014Abstract: The present invention concerns a method for the control of various diseases in bee-hives by applying to the bee-hives an effective amount of an essential oil in a slow-release formulation whereby the term oils embraces but is not limited to oils extractable from plant or the essential component thereof such as monoterpenes like menthol, geraniol, thymol, myrcene, citral, limonene, carene, camphor, eugenol, or cineol (eucalyptol); natural oils like lemon oil, eucalyptus oil, or neem oil; or organic acids like formic acid, acetic acid or oxalic acid. Most preferred are monoterpenes like thymol or menthol. Most preferred is thymol.Type: GrantFiled: January 22, 2001Date of Patent: November 11, 2003Assignee: Vita (Europe) LimitedInventor: Max Watkins
-
Patent number: 6635680Abstract: The present invention describes an aqueous pharmaceutical coating formulation which can be used for coating core elements containing one or more medicaments to achieve controlled release. The coated pharmaceutical formulation provides a release of medicaments in a controlled manner at highly acidic environment such as that of stomach and shows relatively faster release in media with basic pH such as that of the intestine. The coating composition is a heterogenous mixture which comprises (a) at least 75% by weight of a water insoluble polymer which is insoluble in both acidic as well as basic pH; and (b) 1 to 25% by weight of an enteric polymer which is substantially insoluble in water at a pH below 4.5 and which is substantially soluble in water at a pH between above about 6.0, said enteric polymer and water insoluble polymer being present in an amount effective to control-the release of said medicament.Type: GrantFiled: June 10, 2002Date of Patent: October 21, 2003Assignee: Nostrum Pharmaceuticals, Inc.Inventor: Nirmal Mulye
-
Patent number: 6599532Abstract: The present invention provides an osmotic device containing controlled release alprazolam in the core optionally in combination with an anti-psychotic agent, in a rapid release external coat. A wide range of anti-psychotic agents can be used in this device. Particular embodiments of the invention provide osmotic devices having predetermined release profiles. One preferred embodiment of the osmotic device includes an external coat that has been spray coated rather compression coated onto the device. The device with spray coated external core is smaller and easier to swallow than the similar device having a compression coated external coat. The device is useful for the treatment of depression, anxiety or psychosis related disorders.Type: GrantFiled: January 8, 2001Date of Patent: July 29, 2003Assignee: Osmotica Corp.Inventors: Joaquina Faour, Juan A. Vergez
-
Patent number: 6589547Abstract: The present invention is to provide a sustained-release preparation which comprises a compound having angiotensin II antagonistic activity, its pro-drug or their salt, and a biodegradable polymer, and if necessary, a polyvalent metal, and which is highly stable and active and shows angiotensin II antagonistic activity while maintaining circadian rhythm of blood pressure for a long time.Type: GrantFiled: August 9, 2000Date of Patent: July 8, 2003Assignee: Takeda Chemical Industries, Ltd.Inventors: Yasutaka Igari, Akira Saikawa, Yoshiyuki Inada, Shigeru Kamei
-
Patent number: 6585993Abstract: A biocompatible implant for continuous in vivo release of a neurotoxin over a treatment period extending from one month to five years. The implant can be made of casting a solution of a polymer, such as an ethyl vinyl acetate copolymer and the neurotoxin. The neurotoxin can be a botulinum toxin.Type: GrantFiled: March 11, 2002Date of Patent: July 1, 2003Assignee: Allergan, Inc.Inventors: Stephen Donovan, Daniel G. Brady
-
Patent number: 6562835Abstract: Urinary incontinence is alleviated in a mammal by administering to the mammal a urinary incontinence alleviating amount of dextromethorphan, dextrorphan, their mixtures and/or pharmaceutically acceptable salts, alone or in combination with a pharmacologically active agent such as an anticholinergic, sympathomimetic, tricyclic antidepressant, antispasmodic, direct-acting smooth muscle relaxant, estrogen, compound having estrogen-like activity, or any combination of the foregoing.Type: GrantFiled: October 21, 1996Date of Patent: May 13, 2003Assignee: Endo Pharmaceuticals Inc.Inventor: Frank S. Caruso
-
Patent number: 6562332Abstract: The invention provides methods and compositions useful for attracting predatory insects.Type: GrantFiled: December 5, 2000Date of Patent: May 13, 2003Assignee: Iowa State University Research Foundation, Inc.Inventors: Thomas C. Baker, John J. Obrycki, Junwei Zhu
-
Patent number: 6558702Abstract: The present invention relates to a method for the sustained release in vivo of a biologically active agent comprising administering to a subject in need of treatment an effective amount of a sustained release composition comprising a biocompatible polymer having the biologically active agent incorporated therein, and a bisphosphonate wherein the bisphosphonate compound is present in an amount sufficient to modify the release profile of the biologically active agent from the sustained release composition. Pharmaceutical compositions suitable for use in the method of the invention are also disclosed.Type: GrantFiled: April 13, 2001Date of Patent: May 6, 2003Assignee: Alkermes Controlled Therapeutics, Inc.Inventors: James R. Dasch, M. Gary I. Riley
-
Patent number: 6544554Abstract: Controlled-release formulation having such a portion that the core and a drug release layer each of which has been formulated to effect rapid or gradual release of at least one drug the release of which is to be controlled is covered either partly or entirely with a release control layer that is produced by adding pharmaceutically acceptable additives to at least one base selected from among fumaric acid, DL-tryptophan and L-tyrosine and which is substantially free from the drugs the release of which is to be controlled.Type: GrantFiled: November 13, 2000Date of Patent: April 8, 2003Assignee: Chugai Seiyaku Kabushiki KaishaInventors: Hiroyuki Maeda, Yutaka Ogawa, Yoshimitsu Iida
-
Patent number: 6544559Abstract: Sustained-release microparticle composition. The microparticle composition can be formulated to provide multi-phasic release. In one aspect, the composition includes microparticles having more than one rate of release. In another aspect, the composition includes microparticles that exhibit diffusional release and microparticles that exhibit biodegradation release.Type: GrantFiled: January 29, 2002Date of Patent: April 8, 2003Assignees: Alkermes Controlled Therapeutics Inc. II, Janssen ParmaceuticaInventors: Jean Mesens, Michael E. Rickey, Thomas J. Atkins
-
Patent number: 6540991Abstract: A stabilized insect mating disruption pheromone compositions comprising an insect pheromone and 2,2′-Methylenebis(6-t-butyl-p-cresol). Methods of use and microcapsules containing these compositions are also provided.Type: GrantFiled: April 6, 2001Date of Patent: April 1, 2003Assignee: 3M Innovative Properties CompanyInventors: Darryl F. Klassen, David J. Muir
-
Patent number: 6524624Abstract: A two-part disinfecting systems, as well as disinfecting compositions and methods for making and using the same. The two-part disinfecting system contains a first part and a second part adapted to be mixed to yield an aqueous disinfecting composition, wherein the first part comprises a chlorite and the second part comprises an acid and an optional oxidizable colorant, and wherein the first part, the second part, or both the first and second parts comprise an alpha olefin sulfonate.Type: GrantFiled: May 16, 2001Date of Patent: February 25, 2003Assignee: Alcide CorporationInventors: Joseph Morelli, C. Cayce Warf, Jr., Maura Aldrich, Cecilia Moser Morse, Jean Wiley